Market Research Logo

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H2 2016

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H2 2016’, provides in depth analysis on Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted pipeline therapeutics.

The report provides comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
    • The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


    Introduction
    Global Markets Direct Report Coverage
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Overview
    Therapeutics Development
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Products under Development by Stage of Development
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Products under Development by Therapy Area
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Products under Development by Indication
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Products Glance
    Early Stage Products
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Products under Development by Companies
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Products under Development by Universities/Institutes
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment
    Assessment by Monotherapy/Combination Products
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development
    Aurigene Discovery Technologies Limited
    Celgene Corporation
    Trillium Therapeutics Inc.
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
    B-6H12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CC-90002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease and Kidney Transplantation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptide to Inhibit CD47 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Proteins to Inhibit CD47 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit CD47 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TTI-508 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TTI-621 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TTI-622 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Dormant Projects
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Featured News & Press Releases
    Jun 07, 2016: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress
    May 18, 2016: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting
    Apr 14, 2016: Trillium to Provide Update on CD47 Program at the 2016 American Association for Cancer Research Annual Meeting
    Mar 10, 2016: Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program
    Feb 03, 2016: Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47
    Dec 03, 2015: Trillium to Provide Update on CD47 Immune Checkpoint Inhibitor Program at the 2015 American Society of Hematology Annual Meeting
    Sep 30, 2015: Trillium Therapeutics Provides Update on CD47 Program
    Apr 16, 2015: Trillium To Provide Update On CD47 Program At The 2015 American Association For Cancer Research Annual Meeting
    May 31, 2013: Engineered Molecules Boost Immune Attack On Cancer
    Apr 04, 2012: Trillium Provides Update On Anti-CD47 Cancer Program
    Dec 02, 2010: Trillium To Present Preliminary Results From Cancer Stem Cell Program At ASH Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for, H2 2016
    Number of Products under Development by Therapy Area, H2 2016
    Number of Products under Development by Indication, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Number of Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Assessment by Monotherapy/Combination Products, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Pipeline by Aurigene Discovery Technologies Limited, H2 2016
    Pipeline by Celgene Corporation, H2 2016
    Pipeline by Trillium Therapeutics Inc., H2 2016
    Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for, H2 2016
    Number of Products under Development by Therapy Area, H2 2016
    Number of Products under Development by Top 10 Indication, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy/Combination Products, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report